ASCO 2014: Pharmacyclics, Janssen's Imbruvica shines in CLL
This article was originally published in Scrip
Executive Summary
Imbruvica (ibrutinib) from Pharmacyclics and Johnson & Johnson's Janssen subsidiary sets a high bar for other chronic lymphocytic leukemia (CLL) therapies in development with high response rates and strong survival improvements versus GlaxoSmithKline's Arzerra (ofatumumab) in relapsed and refractory CLL patients.